Key result
Planned meta-analysis compares major cardiovascular events and cardiovascular mortality between lean and non-lean MASLD phenotypes.
Why the study?
Cardiovascular disease is the primary driver of mortality across the MASLD spectrum, yet debate persists on whether normal-weight patients face a lower or paradoxically higher cardiovascular risk than those with the classic non-lean phenotype, with existing studies yielding conflicting results.
Does the lean MASLD phenotype alter the long-term risk of major adverse cardiovascular events (MACE) and cardiovascular mortality compared to the non-lean MASLD phenotype?
Meta-Analysis
Does the lean MASLD phenotype alter the long-term risk of major adverse cardiovascular events (MACE) and cardiovascular mortality compared to the non-lean MASLD phenotype?
This planned systematic review and meta-analysis aims to clarify the long-term cardiovascular risk profile of normal-weight (lean) MASLD patients compared to non-lean patients to inform cardiovascular screening and risk stratification.
Answers are grounded in this paper and cite their sources.
Cardiovascular risk stratification in lean MASLD remains uncertain; planned meta-analysis will determine adjusted HRs for MACE versus non-lean phenotype.
This systematic review and meta-analysis is designed to map out the long-term cardiovascular risks associated with "lean" MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease). Even though cardiovascular disease is the primary driver of mortality across the MASLD spectrum, there is still an active debate in the medical community about whether normal-weight patients face a lower risk or a paradoxically higher risk compared to the classic, non-lean phenotype. Our main goal is to pool data from longitudinal cohort studies to get a definitive, adjusted Hazard Ratio for major adverse cardiovascular events (MACE) and cardiovascular mortality. We also plan to use subgroup and sensitivity analyses to dig into why different studies have come up with conflicting results—looking closely at things like geographic differences and baseline metabolic health. Finally, we will use the GRADE framework to evaluate the overall certainty of the current evidence. Methodologically, we are running a comprehensive search across PubMed, EMBASE, the Cochrane Library, and Scopus from inception through June 2026. Two reviewers will handle study selection, data extraction, and quality appraisal (using the Newcastle-Ottawa Scale) independently in duplicate to minimize errors. Statistically, we are using a DerSimonian-Laird random-effects model to handle the synthesis. Ultimately, we expect this project to provide a clear, reliable risk profile for lean MASLD patients. The data generated should help clinicians better stratify patient risk and update screening guidelines for normal-weight individuals who might otherwise be missed in routine cardiovascular checkups.
No takes yet. Share an insight, caveat, or question.
Irshid et al. (2026) conducted a meta-analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Lean (normal-weight) MASLD phenotype vs. Non-lean MASLD phenotype was evaluated on Major adverse cardiovascular events (MACE) and cardiovascular mortality. Lean MASLD is being evaluated against non-lean MASLD in a planned meta-analysis of longitudinal cohorts to determine adjusted hazard ratios for major cardiovascular events and cardiovascular mortality (no results reported).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: